Compounding Trends in Crohn’s & Ulcerative Colitis
1.Low-Dose Naltrexone (LDN)
LDN an opioid antagonist, was the subject of a study for the treatment of Crohn's Disease. (18) Patients were administered LDN capsules for a 12 week period. Eighty-nine percent of patients exhibited a response to the therapy and 67% achieved remission. The authors of the study conclude that LDN therapy appears to be an effective and safe treatment for patients with active Crohn's Disease.
We provide patients with LDN in both a capsule and a transdermal cream. Starting dose 0.5mg increasing to 4.5mg on efficacy
2. Sodium Butyrate and 5-ASA
A recent double-blind, placebo-controlled, multicentre study looked at the efficacy of a topical combination of Sodium Butyrate and 5-ASA in patients with Ulcerative Colitis. (16) These patients had previously failed to respond to the use of 5-ASA in combination with Cortisone. 51 patients were enrolled in the study, with 24 patients receiving the SodiumButyrate/5-ASA combination, and 27 patients receiving 5-ASA alone.
From the group of patients that received the Sodium Butyrate/5-ASA combination, 6 patients had remission of the disease, and 12 patients showed improvement. The group of patients that received 5-ASA alone had one patient with remission and 13 patients showing improvement.
The authors concluded that the combination of Sodium Butyrate/5-ASA was significantly more effective than 5-ASA alone.
For patients with Ulcerative Colitis, we offer a Sodium Butyrate/5-ASA suspension that can be dosed in an enema for ease of administration.
3. Elevated Homocysteine
Homocysteine reduction compounded Transdermal gel containing Vitamin B12, Vitamin B6, Folinic Acid, and TMG
Studies have found that a high prevalence of elevated homocysteine is found in patients who have Crohn's Disease and Ulcerative Colitis. This is especially true with Crohn's Disease, where one study found that 52% of Crohn's patients studied had hyperhomocysteinemia. (1)
In addition to the cardiovascular risk factors of having high homocysteine levels, some recent studies have looked at whether high homocysteine levels could play a part in the pathophysiology of Crohn's and Ulcerative Colitis. The conclusion drawn from these studies is that homocysteine is found at high levels in the colonic mucosa of Crohn's and Ulcerative Colitis patients and can lead to a chronic inflammatory state in the colonic mucosa. (8,9)
Many studies have found that Crohn's and Ulcerative Colitis patients have malabsorption issues. (2, 3, 4) For this reason, it may be advisable to replace the missing nutrients that can effectively lower homocysteine levels by a route other than through the gut.
Because of our many positive experiences with using transdermal formulations of vitamins, minerals, and medications, we have created a transdermal gel containing Vitamin B12, Vitamin B6, Folinic Acid, and TMG. These nutrients have been shown to lower homocysteine levels, and several of these nutrients have been found to be deficient in Crohn's and Ulcerative Colitis patients. (1, 5, 6, 7)
4.Vitamin D supplements high dose
A high prevalence of Osteoporosis is associated with Crohn's and Colitis. (3, 4, 10, 11) One of the risk factors for Crohn's and Colitis patients developing Osteoporosis is inadequate levels of Vitamin D. (3, 4, 10, 21)
In order to provide Crohn's and Colitis patients with adequate levels of Vitamin D, and assure proper absorption, we have created high strength Vitamin D Sublingual Drops. This dosing method is very easy, as the patient simply measures out the correct dose and holds the drops under the tongue for thirty seconds. Sublingual dosing bypasses the gut and allows medication to be absorbed directly into the blood stream.
5.Glutathione production support
Crohn's and Colitis patients have abnormally high levels of the inflammatory cytokines NF-Kappa B, TNF-alpha, Nitric Oxide, and IL-6. (12, 13, 17, 19, 20) Studies have shown that by inhibiting these inflammatory cytokines, improvements in disease status can occur, (12, 13, 14, 17, 20)
Patients with Crohn's and Colitis have also been found to have higher levels of Reactive Oxygen Species, which have been implicated as mediators of inflammation. (14, 15) Agents which increase Glutathione (a potent antioxidant) levels were found to reduce the levels of Reactive Oxygen Species and improve disease status. (13, 14, 15)
In order to help reduce the levels of inflammatory cytokines and Reactive Oxygen Species that are elevated in Crohn's and Colitis patients, we have created a supplement to be taken by mouth, called Intra-Cell Powder. Intra-Cell Powder combines Milk Thistle, Green Tea, and Ginkgo in a patented delivery vehicle called a Phytosome.
Plant extracts that are delivered inside a Phytosome have been proven to be much more bioavailable than standard plant extracts. In addition to reducing levels of inflammatory cytokines and Reactive Oxygen Species, the plant extracts in Intra-Cell have all been proven to be potent enhancers of Glutathione synthesis in the body. Alternatively supplements with Transdermal Glutathione itself the strongest intracellular anti-oxidant
6. Supplements free of sugar, starches, gluten, and lactose
The Specific Carbohydrate Diet (SCD Diet) is a very basic way of eating. It eliminates sugar, starches, gluten, and lactose. It is often used to treat a variety of disorders including Crohn's Disease, Ulcerative Colitis, Celiac Disease, and Autism. Many Crohn's/Colitis patients are beginning to adopt the SCD Diet to aid in the healing of the gut.
Many medications and supplements contain fillers that are not to be ingested when following the SCD Diet. For these patients, we provide customised medications and supplements that are free of any fillers or other ingredients that are not allowed on the SCD Diet.
The Compounding Lab
1/45 Crosby Rd, Albion 4010
1. Roblin X, Germain E, Phelip JM, Ducros V, Pofelski J, Heluwaert F, Oltean P, Faucheron JL, Bonaz B., [Factors associated with hyperhomocysteinemia in inflammatory bowel disease: prospective study in 81 patients], Rev Med Interne. 2006 Feb;27(2):106-10. Epub 2005 Dec 5.
2. Macdonald A., Omega-3 fatty acids as adjunctive therapy in Crohns disease., Gastroenterol Nurs. 2006 Jul-Aug;29(4):295-301; quiz 302-3.
3. Reinshagen M, Von Tirpitz C., Diagnosis and management of osteoporosis in inflammatory bowel disease., Minerva Med. 2004 Dec;95(6):481-7.
4. Vestergaard P., Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease., Minerva Med. 2004 Dec;95(6):469-80.
5. Chowers Y, Sela BA, Holland R, Fidder H, Simoni FB, Bar-Meir S., Increased levels of homocysteine in patients with Crohn's disease are related to folate levels., Am J Gastroenterol. 2000 Dec;95(12):3498-502.
6. Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ., Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls., Eur J Clin Nutr. 2000 Jun;54(6):514-21.
7. Fernandez-Banares F, Abad-Lacruz A, Xiol X, Gine JJ, Dolz C, Cabre E, Esteve M, Gonzalez-Huix F, Gassull MA., Vitamin status in patients with inflammatory bowel disease., Am J Gastroenterol. 1989 Jul;84(7):744-8.
8. Morgenstern I, Raijmakers MT, Peters WH, Hoensch H, Kirch W., Homocysteine, cysteine, and glutathione in human colonic mucosa: elevated levels of homocysteine in patients with inflammatory bowel disease., Dig Dis Sci. 2003 Oct;48(10):2083-90.
9. Danese S, Sgambato A, Papa A, Scaldaferri F, Pola R, Sans M, Lovecchio M, Gasbarrini G, Cittadini A, Gasbarrini A., Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease., Am J Gastroenterol. 2005 Apr;100(4):886-95.
10. Schulte CM., Review article: bone disease in inflammatory bowel disease., Aliment Pharmacol Ther. 2004 Oct;20 Suppl 4:43-9.
11. Bernstein CN, Leslie WD., The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol. 2003 Aug;15(8):857-64.
12. Neurath MF, Fuss I, Schurmann G, Pettersson S, Arnold K, Muller-Lobeck H, Strober W, Herfarth C, Buschenfelde KH., Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease., Ann N Y Acad Sci. 1998 Nov 17;859:149-59.
13. Peran L, Camuesco D, Comalada M, Nieto A, Concha A, Adrio JL, Olivares M, Xaus J, Zarzuelo A, Galvez J., Lactobacillus fermentum, a probiotic capable to release glutathione, prevents colonic inflammation in the TNBS model of rat colitis., Int J Colorectal Dis. 2006 Dec;21(8):737-46. Epub 2005 Jul 29.
14. Oz HS, Chen TS, McClain CJ, de Villiers WJ., Antioxidants as novel therapy in a murine model of colitis., J Nutr Biochem. 2005 May;16(5):297-304.
15. Ardite E, Sans M, Panes J, Romero FJ, Pique JM, Fernandez-Checa JC., Replenishment of glutathione levels improves mucosal function in experimental acute colitis., Lab Invest. 2000 May;80(5):735-44.
16. Vernia P, Annese V, Bresci G, d'Albasio G, D'Inca R, Giaccari S, Ingrosso , Mansi C, Riegler G, Valpiani D, Caprilli R; Gruppo Italiano per lo Studio del Colon and del Retto., Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial., Eur J Clin Invest. 2003 Mar;33(3):244-8.
17. Lundberg S, Holst M, Hellstrom PM., Acta Physiol (Oxf)., Expression of iNOS mRNA associated with suppression of colonic contraction in rat colitis., 2006 Aug;187(4):489-94.
18. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS., Low-Dose Naltrexone Therapy Improves Active Crohn's Disease., Am J Gastroenterol. 2007 Jan 11;
19. Reinders CI, Herulf M, Ljung T, Hollenberg J, Weitzberg E, Lundberg JO, Hellstrom PM., Rectal mucosal nitric oxide in differentiation of inflammatory bowel disease and irritable bowel syndrome., Clin Gastroenterol Hepatol. 2005 Aug;3(8):777-83.
20. Pilichos CJ, Kouerinis IA, Zografos GC, Korkolis DP, Preza AA, Gazouli M, Menenakos EI, Loutsidis AE, Zagouri F, Gorgoulis VG, Fotiadis CI., The effect of nitric oxide synthases inhibitors on inflammatory bowel disease in a rat model., In Vivo. 2004 Jul-Aug;18(4):513-6.
21. Pappa HM, Gordon CM, Saslowsky TM, Zholudev A, Horr B, Shih MC, Grand RJ., Vitamin D status in children and young adults with inflammatory bowel disease., Pediatrics. 2006 Nov;118(5):1950-61.